Methandienone 50 - Genetic Pharmaceuticals

Between 1965 and 1983, Methandienone enjoyed a brief period of medical legitimacy in the U.S., initially approved for treating conditions such as osteoporosis and pituitary dwarfism. Although considered “Probably Effective” by the FDA, Ciba and its successors failed to provide conclusive clinical evidence, resulting in the drug's eventual withdrawal from the American pharmaceutical market. Its official removal came in 1983, effectively ending its regulated presence, even as underground use among athletes and bodybuilders persisted long after.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Methandienone 50 by Genetic Pharmaceuticals, consult with your doctor or healthcare professional.